¹⁸F-氟脱氧葡萄糖PET评估转移性胃肠道间质瘤患者在400mg剂量进展后接受800mg伊马替尼治疗的早期反应
Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
作者信息
Chacón Matías, Eleta Martín, Espindola Adriel Rodríguez, Roca Enrique, Méndez Guillermo, Rojo Sandra, Pupareli Carmen
机构信息
Grupo Argentino de Tumores Estromales Digestivos (GATE-D), Buenos Aires 1426, Argentina.
出版信息
Future Oncol. 2015;11(6):953-64. doi: 10.2217/fon.14.292.
INTRODUCTION
Imatinib is the standard first-line therapy for advanced gastrointestinal stromal tumor. (18)F-fluorodeoxyglucose PET computed tomography (FDG PET/CT) shows a faster response than computed tomography in nonpretreated patients.
PATIENTS & METHODS: After disease progression on imatinib 400 mg, 16 patients were exposed to 800 mg. Tumor response was evaluated by FDG PET/CT on days 7 and 37. Primary objective was to correlate early metabolic response (EMR) with progression-free survival (PFS).
RESULTS
EMR by FDG PET/CT scan was not predictive of PFS. Median PFS in these patients was 3 months. Overall survival was influenced by gastric primary site (p = 0.05).
CONCLUSION
The assessment of EMR by FDG PET/CT in patients with advanced gastrointestinal stromal tumor exposed to imatinib 800 mg was not predictive of PFS or overall survival.
引言
伊马替尼是晚期胃肠道间质瘤的标准一线治疗药物。（18）F-氟脱氧葡萄糖正电子发射断层扫描计算机断层扫描（FDG PET/CT）在未接受过治疗的患者中显示出比计算机断层扫描更快的反应。
患者与方法
在400mg伊马替尼治疗疾病进展后，16例患者接受800mg伊马替尼治疗。在第7天和第37天通过FDG PET/CT评估肿瘤反应。主要目的是将早期代谢反应（EMR）与无进展生存期（PFS）相关联。
结果
FDG PET/CT扫描的EMR不能预测PFS。这些患者的中位PFS为3个月。总生存期受胃原发部位影响（p = 0.05）。
结论
在接受800mg伊马替尼治疗的晚期胃肠道间质瘤患者中，通过FDG PET/CT评估EMR不能预测PFS或总生存期。
Zotero 插件